CD45 IN CUTANEOUS MELANOMA CELLS AS A MANIFESTATION OF TUMOR ATYPIA

M. B Aksenenko; L. A Shestakova; T. G Ruksha

doi:10.17816/dv36755

Russian Journal of Skin and Venereal Diseases ›› 2013, Vol. 16 ›› Issue (4) : 6 -8. DOI: 10.17816/dv36755

Articles

research-article

CD45 IN CUTANEOUS MELANOMA CELLS AS A MANIFESTATION OF TUMOR ATYPIA

Author information +

History +

PDF

Abstract

The expression of CD45 (hemopoietic cell marker) in cutaneous melanoma cells was studied in 96 patients (40 men and 56 women). The expression was detected in 17.5% patients, mainly with Clark’s tumor invasion levels IV and V and Breslow’s thickness of the tumor 3.7±1.09 mm. Data on the relationship between this marker’s expression and clinical morphological characteristics of the disease are presented. The differential diagnosis of cutaneous melanoma is discussed.

Keywords

CD45 / cutaneous melanoma / CD45 / necrotization

Cite this article

Download citation ▾

M. B Aksenenko, L. A Shestakova, T. G Ruksha. CD45 IN CUTANEOUS MELANOMA CELLS AS A MANIFESTATION OF TUMOR ATYPIA. Russian Journal of Skin and Venereal Diseases, 2013, 16(4): 6-8 DOI:10.17816/dv36755

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Stoeter D., de Liguori Carino N., Marshall E., Poston G.J., Wu A. Extensive necrosis of visceral melanoma metastases after immunotherapy. World J. Surg. Oncol. 2008; 6: 30. doi: 10.1186/14777819-6-30.

[2]	Bachmann I.M., Ladstein R.G., Straume O., Naumov G.N., Akslen L.A. Tumor necrosis is associated with increased alpha-v beta-3 integrin expression and poor prognosis in nodular cutaneous melanomas. BMC Cancer. 2008; 8: 362. doi: 10.1186/1471-2407-8-362.

[3]	Judkins A.R., Roberts S.A., Livolsi V.A. Utility of immunohistochemistry in the evaluation of necrotic thyroid tumors. Hum. Pathol. 1999; 30(11): 1373-6.

[4]	Chen N., Gong J., Chen X., Xu M., Huang Y., Wang L., et al. Cytokeratin expression in malignant melanoma: potential application of in-situ hybridization analysis of mRNA. Melanoma Res. 2009; 19(2): 87-93.

[5]	Aisner D.L., Maker A., Rosenberg S.A., Berman D.M. Loss of S-100 antigenicity in metastatic melanoma. Hum. Pathol. 2005; 36(9): 1016-9.

[6]	Saleh F.H., Crotty K.A., Hersey P., Menzies S. W., Rahman W. Autonomous histopathological regression of primary tumors associated with specific immune responses to cancer antigens. J. Pathol. 2003; 200(3): 383-95.

[7]	Nonaka D., Laser J., Tucker R., Melamed J. Immunohistochemical evaluation of necrotic malignant melanomas. Am. J. Clin. Pathol. 2007; 127(5): 787-91.

[8]	Taetle R., Ostergaard H., Smedsrud M., Trowbridge I. Regulation of CD45 expression in human leukemia cells. Leukemia. 1991; 5(4): 309-14.

[9]	Judkins A.R., Montone K.T., Livolsi V.A., van de Rijn M. Sensitivity and specificity of antibodies on necrotic tumor tissue. Am. J. Clin. Pathol. 1998; 110(5): 641-6.